Xencor Inc (XNCR) income statement
XNCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 5/30188% above fair value
$33.26−0.75 (-2.21%)
Close on Nov 20, 2026Market cap $2.47BP/E –Yield –
Xencor Inc income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -205.8%
- Net margin
- -155.6%
- Return on equity, FY2025
- -14.0%
Financial strength
- Current ratio
- 6.39
- Debt to equity
- 0.21
- Debt to assets
- 14.5%
- Cash to current liabilities
- 54.6%
Valuation
- P/E ratio
- –
- Price to sales
- 23.56
- Price to book
- 4.91
- Dividend yield
- –
See a number that looks wrong?